Novartis AG — News

Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the first quarter, according to its most recent filing with the SEC. The firm purchased 3,326 shares of the company's stock, valued at approximately $508,000. Several other hedge funds have also recently bought and sold shares of

defenseworld.net - 2026-08-01 04:21:27

Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,962 shares of the company's stock, valued at approximately $3,507,000. A number of other institutional investors have also recently

defenseworld.net - 2026-07-30 03:28:05

These companies' recent headwinds shouldn't lead to decreased payouts.

fool.com - 2026-07-29 13:00:00

Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,359 shares of the company's stock, valued at approximately $1,888,000. A number of other large

defenseworld.net - 2026-07-27 05:05:07

Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 203,045 shares of the company's stock after acquiring an additional 24,096 shares during the quarter.

defenseworld.net - 2026-07-27 04:18:59

Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.

seekingalpha.com - 2026-07-22 09:28:33

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-21 17:43:56

Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug Entresto. CEO Vas Narasimhan discussed the company's strategic focus on navigating significant patent expiries in the first half of the year, followed by a growth phase in the second half fueled by investments in the pipeline and new product launches.

youtube.com - 2026-07-21 17:16:29

Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.

zacks.com - 2026-07-21 12:46:10

GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.

zacks.com - 2026-07-21 11:50:35

Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.

marketbeat.com - 2026-07-21 11:07:39

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-07-21 10:31:20

Stock futures are rising after three straight days of declines for major indexes; chip stocks are leading the rebound as volatility in the AI trade persists; several big-name companies reported earnings this morning ahead of Big Tech results tomorrow; Nebius shares are surging on news Nvidia as increased its stake in the Dutch AI infrastructure company; and SpaceX shares are rising after closing lower for the seventh consecutive sessions. Here's what you need to know today.

investopedia.com - 2026-07-21 08:50:49

Novartis AG (NYSE:NVS) reported better-than-expected second-quarter earnings on Tuesday as strong demand for its priority medicines offset the impact of generic competition, while the Swiss drugmaker reaffirmed its full-year 2026 guidance.

benzinga.com - 2026-07-21 08:21:17

Novartis chief executive ​officer Vas Narasimhan ‌said on Tuesday he plans ​to stick ​around for the Swiss ⁠drugmaker's next ​phase of growth, ​ahead of a series of high-stakes trial ​data expected ​for the company in ‌the ⁠second half of the year.

reuters.com - 2026-07-21 07:21:17

Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-expected costs helped the Swiss drugmaker offset a sharp decline in sales of its top-selling heart failure drug Entresto.

invezz.com - 2026-07-21 03:26:17

Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.

wsj.com - 2026-07-21 01:33:00

Novartis' second-quarter core operating profit beat ​market expectations on Tuesday, ‌helped by strong sales of cancer and ​multiple sclerosis drugs.

reuters.com - 2026-07-21 01:10:37

Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto. We are encouraged by the early trajectory of our recent launches, Rhapsido in CSU and Itvisma. We also made meaningful pipeline progress, highlighted by updated Kisqali overall survival data in early breast cancer and the FDA accelerated approval submission for del-zota in DMD. We are on track for multiple important readouts ahead in the second half, and remain on track to deliver our full-year guidance and mid-term outlook.

globenewswire.com - 2026-07-21 01:00:00

While the first quarter showed weaker revenue and earnings, management had already warned that 2026 would begin with significant pressure from generic competition. The key question for traders and investors is whether Novartis' newer medicines are growing quickly enough to offset those losses.

fxempire.com - 2026-07-20 11:15:12

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

fool.com - 2026-07-20 10:44:01

Dimensional Fund Advisors LP reduced its stake in shares of Novartis AG (NYSE: NVS) by 4.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,110,116 shares of the company's stock after selling 414,278 shares during the period. Dimensional Fund

defenseworld.net - 2026-07-20 05:18:46

Boston Common Asset Management LLC lessened its position in shares of Novartis AG (NYSE: NVS) by 4.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,116 shares of the company's stock after selling 5,150 shares during the quarter. Novartis comprises

defenseworld.net - 2026-07-20 04:37:05

Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in ‌the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation.

reuters.com - 2026-07-20 01:04:13

NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.

zacks.com - 2026-07-17 15:26:08

Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

zacks.com - 2026-07-16 10:36:33

The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

seekingalpha.com - 2026-07-13 13:45:49

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

fool.com - 2026-07-09 12:12:04

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

fool.com - 2026-07-09 08:15:04

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

marketbeat.com - 2026-07-08 12:36:02

Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.

seekingalpha.com - 2026-07-07 08:40:52

NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.

zacks.com - 2026-07-06 15:41:05

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.

wsj.com - 2026-07-06 01:52:00

Swiss drugmaker Novartis said on Monday it had ​agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected ​to close in the second ​half of 2026.

reuters.com - 2026-07-06 01:26:17

Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.

zacks.com - 2026-07-02 15:16:14

The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:

marketbeat.com - 2026-07-01 11:05:28

Novartis (NVS) is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therapy uses targeted r

gurufocus.com - 2026-06-25 08:34:00

Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth ​up to about $1.9 billion, aiming to develop therapies ‌for historically hard-to-drug cancer targets.

reuters.com - 2026-06-24 08:15:00

BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop and commercialize small molecule therapies against promising but historically undruggable oncology targets. The agreement underscores the productivity and breadth of Antares' discovery capabilities, which have repeatedly delivered development candi.

businesswire.com - 2026-06-24 07:00:00

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

zacks.com - 2026-06-23 17:21:05

Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.

zacks.com - 2026-06-15 11:30:30

The Schwab Fundamental International Equity ETF (NYSEARCA:FNDF) pays semi-annual distributions sourced from a basket of developed-market dividend payers outside the United States, and at roughly $54 a share the fund has quietly become a core income holding for investors who want global diversification without chasing yield.

247wallst.com - 2026-06-13 10:00:14

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial7. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines7. “Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.” The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common8. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines. “Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido's proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis' commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.” Primary endpoint results at Week 12 in the RemIND trial1

globenewswire.com - 2026-06-12 05:36:00

Novartis said on Thursday an experimental drug, which it acquired ​as part of its $12 billion takeover of ‌Avidity, showed promise in an early-to-mid-stage study in patients with a type ​of genetic muscle disorder characterized ​by slowly progressive muscle weakness.

reuters.com - 2026-06-11 17:41:12

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.

zacks.com - 2026-06-11 14:26:18

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

zacks.com - 2026-06-11 14:26:14

Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy del-brax met both its primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disease.

benzinga.com - 2026-06-11 09:14:12

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax indicates potential to become the first disease-modifying treatment for FSHD, a progressive and irreversible neuromuscular disease affecting approximately 45-87k people in the US and EU Novartis plans to engage global regulatory authorities on Phase I/II data; Phase III study currently enrolling Basel, June 11, 2026 – Novartis announced today that the biomarker cohort of the FORTITUDE Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with facioscapulohumeral muscular dystrophy (FSHD).

globenewswire.com - 2026-06-11 01:00:00

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collaboration expands the existing relationship between the companies and reflects a shared commitment to unlock the full value of induced proximity approac.

businesswire.com - 2026-06-10 07:00:00